Abstract
During recent years there has been a surge in developing and applying physiologically based pharmacokinetic (PBPK) models in pregnant women to better understand and predict changes in drug pharmacokinetics throughout pregnancy. As a consequence, the number of publications focusing on pregnancy PBPK models has increased substantially. However, to date these models, especially across various platforms, have not been systematically evaluated. Hence, this review aims to assess published PBPK models in pregnancy used for therapeutic purposes.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
MeSH terms
-
Animals
-
Dosage Forms
-
Drug Administration Routes
-
Drug Development / methods*
-
Drug Interactions
-
Drug-Related Side Effects and Adverse Reactions / etiology
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / blood
-
Enzyme Inhibitors / pharmacokinetics*
-
Female
-
Gastrointestinal Absorption
-
Gestational Age
-
Humans
-
Lactation
-
Maternal Exposure
-
Maternal-Fetal Exchange
-
Membrane Transport Modulators / administration & dosage
-
Membrane Transport Modulators / adverse effects
-
Membrane Transport Modulators / blood
-
Membrane Transport Modulators / pharmacokinetics*
-
Models, Biological
-
Patient Safety
-
Pharmacokinetics*
-
Placental Circulation
-
Pregnancy
-
Risk Assessment
-
Risk Factors
-
Species Specificity
Substances
-
Dosage Forms
-
Enzyme Inhibitors
-
Membrane Transport Modulators